Descripción de la oferta
Granada, Spain Call4Entrepreneurs - The Collider
About the job CEO ENDOMET (The Collider Programme)
ENDOMET | Switching On Endogenous Energy
CEO & Co-Founder Opportunity | Biotech | Rare Diseases & Womens Health
Are you looking for a high-impact entrepreneurial opportunity to build a science-driven biotech spin-off addressing rare mitochondrial diseases and female reproductive health?
ENDOMET, a deep-tech biotech project backed by the University of Granada, is developing MVP11, a first-in-class small molecule that restores mitochondrial energy by activating endogenous Coenzyme Q (CoQ) biosynthesis. The project is seeking an entrepreneurial CEO to join the founding team and lead the creation of the spin-off.
About ENDOMET
A large number of frequent and rare diseases are characterized by CoQ deficiency, leading to impaired mitochondrial energy production.
Current standard care relies on exogenous CoQ10 supplementation, which underperforms due to poor bioavailability, limited delivery to target tissues and insufficient mitochondrial impact.
ENDOMET has developed a small molecule designed to reach mitochondria and stimulate endogenous CoQ biosynthesis, enabling cells to restore their own energy production. This approach represents a true therapeutic restoration, rather than supplementation.
The technology initially targets rare CoQ-related disorders with high unmet medical need, with potential expansion into female reproductive health through partnering and out-licensing.
The teams vision is to position ENDOMET as a first-in-class mitochondrial energy platform, with applications expandable to additional rare and common diseases through partnering and out-licensing.
Why ENDOMET
Orphan Drug Designation (ODD) granted by the EMA and FDA.
Strong and defensible IP position, including active IP and PCT protection.
Positive clinical signals from compassionate-use cases:Improved quality of life, faster and higher clinical response (renal and neurological), easy oral administration,positive feedback from clinicians and caregivers.
Strong founding team commitment, with a scientific co‑founder committed to joining as full‑time CTO upon spin‑off incorporation.
Your challenge as CEO & Co-Founder (Next 6 Months)
You will lead ENDOMET through a critical inflection point, focusing on:
Defining the business and financial plan for the company.
Spin‑off creation and alignment with the Technology Transfer Office.
Strengthening the regulatory and GMP strategy and expansion of compassionate use.
Leading fundraising efforts (public and private).
Establishing strategic partnerships with GMP manufacturers and industry partners.
Relevant equity as CEO & Co‑Founder upon company incorporation.
€6,000 stipend during the validation phase (3 monthly instalments of €2,000).
Access to The Collider venture‑building programme, which includes experts and hands on support in market validation, finance, marketing, IP, regulatory, fundraising, team formation and company structuring.
Access to The Collider and MWCapital ecosystem (4YFN, Mobile World Congress, corporate & investor networks).
Opportunity to access a participative loan of up to €50,000 to finance the first phases of the project.
Coworking space in Barcelona (Tech Barcelona – Pier 01).
Last but not least, our venture builder support continues for two years after incorporation, giving founders access to in‑kind services, a strong community and portfolio perks.
This Opportunity Is for You If
You are an entrepreneur with experience in biotech, pharma or life sciences.
Previous experience as founder or co‑founder is highly valued.
Strong understanding of rare diseases, regulatory pathways and go‑to‑market strategies.
Experience with technology transfer and academic spin‑offs.
Comfortable operating at the intersection of science, regulation and business.
Hands‑on, resilient leader with long‑term vision.
Eligible to work in Spain (passport or valid visa required).
#J-18808-Ljbffr
